Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas a phase II trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 2, 1998, Pages 151-154

  Abad, Albert ^a,k   Massuti, B ^b   Blanco, E ^c   Carrato, A ^d   Maurel, J ^a   Cervantes, A ^e   Aranda, E ^f   Anton A ^g   Vicent, J M ^h   Dorta, J ⁱ   Garcia De Paredes, M L ^j   Ariza, A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

^d Hospital General   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f Hospital Universitario Reina   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^j Pharmacia and Upjohn SA   (Spain)

^k UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Chemoresistance; Epirubicin; P glycoprotein; Pancreatic cancer

Indexed keywords

EPIRUBICIN; QUINIDINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MULTIDRUG RESISTANCE; NAUSEA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; QUINIDINE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031900378     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199804000-00012     Document Type: Article

References (20)

1. Cersonimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity and adverse effects of an adriamycin analogue. J Clin Oncol 1986;4:425-39.
2. Gastrointestinal Tumor Study Group. Phase II trials of the single agents baker's antifol, diaziquone, and epirubicin in advanced pancreatic carcinoma. Cancer Treat Rep 1987;71:865-7.
3. Topham C, Glees J, Rawson NSB, et al. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer 1991;64:179-81.
4. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistence gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci 1987;84:7735-8.
5. Pinedo H, Giaccone G. P-glycoprotein: a marker of cancer-cell behavior. N Engl J Med 1995;333:1417-9.
6. Abad A, Masuti B, Camps C, et al. Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma [letter]. Eur J Cancer 1994;30A:1043.
7. Lehnert M, Emerson S, Dalton WS, et al. Identification of potentially useful chemosensitizers(CS) to reverse multidrug resistance (MDR1) [abstract]. Eur J Cancer 1991; Suppl:210.
8. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981;47:207-14.
9. Kornek G, Raderer M, Funovics J, et al. Dexverapamil (DVPM), epirubicin (EPI) plus GmCSF in advanced pancreatic cancer: phase I/II study [abstract]. Ann Oncol 1994; Suppl:348.
10. Chen G, Jaffrezou JP, Fleming WH, et al. Prevalence of multi-drug resistence related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 1994;54:4980-7.
11. Tobe SW, Noble-Topham SE, Andrulis IL, et al. Expression of the multiple drug resistence gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res 1995;1:1611-5.
12. Kuttesh JF, Parham DM, Luo X, et al. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 1996;14:886-900.
13. Seidman AD, Hochhauser D, Gollup M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-84.
14. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-82.
15. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-43.
16. Pellegata NS, Sessa F, Bonato M, et al. K-ras and p53 gene mutations in pancreatic cancer:ductal and nonductal tumors progress though different genetic lesions. Cancer Res 1994;54:1556-60.
17. Han HJ, Yanagisawa A, Kato Y, et al. Genetic instability in pancreatic cancer and poorly differenciated type of gastric cancer. Cancer Res 1993;53:5087-9.
18. Brentnall TA, Chen R, Lee JG, et al. Microsatellite instability and k-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 1995;55:4264-7.
19. Lowe SW, Bodis S, McClatchey A, et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994;226:807-9.
20. Anthoney DA, McIlwrath AJ, Gallagher WM, et al. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996;56:1374-81.